AQBiosim's quantum simulation approach could expedite drug development and create safer and more effective drugs.
Since emerging from stealth mode in June 2023, AQBiosim has won praise and partnerships for being one of the most significant entrants into the biopharma molecular simulation market.
AQBiosim, which is a division of SandboxAQ, a simulation company serving several other industries, employs quantum mechanics with existing classical...
Create an account to read this article
Already a subscriber?
The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.
An interactive look at pharma, medtech and diagnostics deals made during September 2025. Data courtesy of Biomedtracker.
For biotech CEOs navigating today’s capital crunch, understanding what sophisticated investors actually look for can mean the difference between a successful raise and months of rejected pitches.
Eight $1bn+ alliances were penned in September, and four exceeded $2bn. In the top alliance by deal value, Monte Rosa Therapeutics will apply its AI-enabled QuEEN platform for the discovery and development of novel molecular glue degraders for immune-mediated diseases.
Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The billion-dollar startup has doubled headcount, released massive datasets and is advancing therapeutics, but the hard part lies ahead.
